Breaking News, Financial News

GlaxoSmithKline

Avandia losses, plus generics put a drain on revenues.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline 3Q10 3Q10 Revenues: $10.6 billion (-2%) 3Q10 Earnings: $2.1 billion (-2%) YTD Revenues: $32.6 billion (+4%) YTD Earnings: $3.8 billion (-38%) Comments: Avandia sales for the quarter dropped 65% to $111 million, and will become negligible after 4Q10, a result of severe restrictions in the U.S. and withdrawal in Europe. For the year, U.S. pharma revenues have dropped 7% to $8.9 billion, primarily due to Avandia, generic Valtrex, and loss of Boniva and WellButrin XL. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters